{"Exaggerate": "The claim exaggerates by stating that \"China owns the patent for the drug remdesivir,\" when in fact, Gilead Sciences holds the U.S. patent for the drug as a coronavirus treatment.", "Lack enough support": "The claim lacks enough support as there is no evidence or recognized patent for remdesivir being owned by any Chinese institution.", "Problematic assumption": "The claim makes a problematic assumption that China owns the patent for remdesivir based on a graphic shared on Facebook, which may not be reliable or accurate.", "Exist alternative explanation": "An alternative explanation is that Chinese researchers filed for a patent to use remdesivir as a treatment against COVID-19, but it does not imply ownership of the patent.", "Contradict fact": "The claim contradicts the fact that Gilead Sciences is the only organization entitled to intellectual property rights over remdesivir as a treatment for COVID-19.", "Falters at times": "The claim falters at times by presenting misleading information and conspiracy theories surrounding the ownership and utility of remdesivir.", "Understate": "There is no understatement bias present in the claim."}